Menu
Log In Sign Up
Article

unp peptide UNP is working on a new approach centred on macrocycles and cyclic peptides

Published October Oct 17, 2026 12:20 PM

In the rapidly evolving landscape of advanced biochemistry, the term "peptide" has transcended its traditional associations with basic skincare or fundamental biology. As someone who follows the intersection of machine learning and molecular engineering, I have been Big news with the announcement of Unnatural Products (UNP)raising a M Series Bto advance macrocyclic peptide therapeutics. Unnatural Read more closely tracking the progress of Unnatural Products (UNP). Their work represents a paradigm shift in how we conceptualize synthetic molecular structures.

The Innovation Behind UNP Peptide Platforms

UNP has created the first platform to repeatably engineer synthetic macrocyclic peptides, a feat that was once considered nearly impossible in the realm of drug discovery. Unlike standard linear chains, these macrocycles are small chains of amino acids that form loops, providing a unique structural rigidity. This design is crucial because macrocyclic peptides are designed to engage complex targets while maintaining the capability to pass throug Peptides Manufacturers in India | Global Exporters h cell membranes, much like small molecule drugs.

From my perspective, the most impressive aspect of their approach is how UNP’s proprietary platform integrates machine learning and parallel chemistry. By leveraging an AI-based macrocycle discovery platform, they can navigate chemical spaces that were previously deemed "undruggable." This is not just theoretical; the company is a biotech developing orally-delivered macrocyclic peptides that aim to Unnatural Products, Inc. - Drug pipelines, Patents, Clinical bridge the gap between traditional biologics and small-molecule chemistry.

Strategic Milestones and Industry Impact

The industry has taken significant notice of these developments. The recent news regarding UNP raising a $45M Series B underscores the confidence investors have in their pipeline. Furthermore, high-profile collaborations demonst 4 Dec 2024—UNP'sproprietary platform combines massively parallel chemistry with machine learning to design and optimize macrocyclicpeptides. This Read more rate the tangible value of their research:

* Partnerships: Merck & Co. has signed a deal with Santa Cruz, California–based Unnatural Products (UNP) to develop macrocyclic peptide candidates.

* Expansion: Novartis has entered a strategic licensing agreement with UNP for peptide therapeutics, with potential milestone payments reaching into the billions.

* Immunology: Their work with partners like Argenx highlights the versatility of these molecules in addressing complex disease targets.

Technical Precision: The Case of UNP-6457

One of the most verifiable examples of their success is the molecule known as UNP-6457. In their research, they utilized DNA-encoded cyclic peptide libraries to discover this specific nonapeptide. The data shows it inhibits the MDM2-p53 interaction with an IC50 of 8.9 nM. This level of potency is a testament to the effectiveness of their AI-driven design processes.

Understanding the Landscape

When discussing the broader field, it is important to distinguish between various types of molecules. While many are familiar with basic peptides in consumer pro 4 Dec 2024—UNP'sproprietary platform combines massively parallel chemistry with machine learning to design and optimize macrocyclicpeptides. This Read more ducts, the macrocyclic peptide therapeutics developed by UNP are in a different league. They are engineering these structures to be orally-delivered macrocyclic peptides, which solves a major hurdle for this class of molecules—bioavailability.

As I look towa Novartis enters licensing agreement with UNP for peptide therapeutics rd the future of this field, it is clear that the combination of machine learning and massively parallel chemistry is unlocking new potential. Whether it is refining the design of cyclic peptide companies or advancing the development of macrocyclic peptide-based therapies, the work being done at UNP is setting a new standard Thanks C&EN for covering our recent news with argenx today. "Macrocyclic peptides are small chains of amino acids that formloops. .

The transition from traditional, manual discovery to the AI-augmented synthesis of macrocycles is a fascinating journey to witness. For those of us interested in the cutting edge of molecular science, the progress of UNP serves as a primary example of how innovation can transform our capability to interact with the building blocks of life. By focusing on these specialized loops and structures, the team at UNP is effectively rewriting the rules of what is possible in molecular design.

Leave a Comment
Get new articles in your inbox

News, updates and freebies. No spam, unsubscribe anytime.